NANOVIRICIDES, INC.
NNVC evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $33.2M
- Lead Asset:
- nv-387 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for NNVC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NNVC
NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a nanomedicine-based platform (nanoviricides™) for antiviral drugs, with its lead candidate NV-387 having completed a Phase I trial and currently preparing for Phase II trials targeting MPox and respiratory viral infections.
Key risk: No revenue or products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$33.2M
Cash Runway
—
Lead Asset
nv-387 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates for NANOVIRICIDES, INC..
NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a nanomedicine-based platform (nanoviricides™) for antiviral drugs, with its lead candidate NV-387 having completed a Phase I trial and currently preparing for Phase II trials targeting MPox and respiratory viral infections.
- Lead drug candidate NV-387 has completed a Phase Ia clinical trial [sec_mda · as of 2026-09-28].
- Cash and equivalents were $2.8M as of June 30, 2026, with an additional $3.4M raised net of fees on July 27, 2026 [sec_mda · as of 2026-09-28].
- The company has no customers, products, or revenues to date [sec · filed 2026-08-21].
- NanoViricides describes itself as a 'Fully-Integrated-Pharmaceutical Company' (FIPCO) with in-house drug discovery, synthesis, testing, and manufacturing capabilities [sec_mda · as of 2026-02-17].
- The company has developed more than ten drug candidates across nearly forty antiviral programs [sec_mda · as of 2026-09-28].
What works
- NanoViricides has a broad pipeline of over ten drug candidates targeting nearly forty antiviral indications, including NV-387 for MPox, respiratory viruses, and others [sec_mda · as of 2026-09-28].
- The company operates as a Fully-Integrated-Pharmaceutical Company (FIPCO) with in-house capabilities from drug discovery to manufacturing, which it states de-risks development and saves time and costs [sec_mda · as of 2026-09-28].
- NV-387 has successfully completed a Phase I safety and tolerability trial, indicating a potential proof-of-concept for the nanoviricide platform [sec_mda · as of 2026-05-15].
What to weigh
- The company has no customers, products, or revenues to date and may never achieve revenues or profitable operations [sec · filed 2026-08-21].
- Cash resources are limited; as of June 30, 2026, cash was $2.8M, and the company states it will need additional funding to continue development through later-stage trials [sec_mda · as of 2026-09-28].
- The company's existing resources, including a $3M line of credit, are not sufficient to fund planned operations for at least 12 months, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2026-02-17].
- Progress to clinic is limited by resources, and the company faces risks from competitor vaccines or drugs that could reduce market potential [sec_mda · as of 2026-09-28].
From the filings
Quoted directly from source documents.
NV-387 has completed a Phase Ia clinical trial.
“NV-387 has completed a Phase Ia”
SEC MD&A · September 28, 2026
The company has no customers, products, or revenues to date.
“We have no customers, products or revenues to date, and may never achieve revenues or profitable operations.”
SEC filings · August 21, 2026
Cash balance was approximately $2.8 million as of June 30, 2026.
“As of June 30, 2026 we had a cash balance of approximately $2.8 million”
SEC MD&A · September 28, 2026
Risks & what to watch (4)›
Key risks
- No revenue or products — Company has no customers, products, or revenues and may never achieve profitable operations [sec · filed 2026-08-21].
- Insufficient cash runway — Cash of $2.8M as of June 30, 2026, plus $3.4M raised July 27, 2026, is not enough for 12 months of planned operations [sec_mda · as of 2026-09-28].
- Going concern uncertainty — Existing resources not sufficient for 12 months; substantial doubt about ability to continue as a going concern [sec_mda · as of 2026-02-17].
- Competitive and market risk — Successful vaccines or competitor drugs could reduce market potential for NV-387 and other candidates [sec_mda · as of 2026-09-28].
What to watch
- Initiation of Phase II clinical trial for NV-387 as a treatment for MPox infections [sec_mda · as of 2026-09-28].
- Initiation of Phase II clinical trial for NV-387 for Viral ARI/SARI, which may support RSV and other respiratory indications [sec_mda · as of 2026-09-28].
- Orphan drug designation filings to the US FDA for NV-387 for MPox, Smallpox, and other viruses [sec_mda · as of 2026-09-28].
- Company's ability to secure additional funding or a collaborative licensing/partnership agreement to sustain operations [sec_mda · as of 2026-09-28].
Sources: SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run NANOVIRICIDES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NANOVIRICIDES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.14
Lead: Phase 2
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
48
Total value held
$1.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 511,477 | $466K |
| geode capital management, llc | 225,381 | $206K |
| ubs group ag | 213,359 | $195K |
| blackrock, inc. | 158,752 | $145K |
| renaissance technologies llc | 134,900 | $123K |
| miller financial services llc | 105,000 | $96K |
| susquehanna international group, llp | 99,031 | $90K |
| vanguard fiduciary trust co | 90,060 | $82K |
| squarepoint ops llc | 58,138 | $53K |
| state street corp | 54,206 | $49K |
Showing top 10 of 48 institutional holders of NANOVIRICIDES, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 3.4%
- Days to cover
- 3.0
- Shares short
- 713,649
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NNVC short interestGovernance
Frequently asked questions
What is the AI investment thesis for NANOVIRICIDES, INC.?
NanoViricides, Inc. is a clinical-stage biopharmaceutical company developing a nanomedicine-based platform (nanoviricides™) for antiviral drugs, with its lead candidate NV-387 having completed a Phase I trial and currently preparing for Phase II trials targeting MPox and respiratory viral infections.
What is NANOVIRICIDES, INC.'s lead drug candidate?
NANOVIRICIDES, INC.'s most advanced tracked candidate is nv-387 (Phase 2) for COVID infection, RSV infection, Influenza, Smallpox, MPox.
Who is the CEO of NANOVIRICIDES, INC.?
Dr. Anil R. Diwan Ph.D. is the chief executive officer of NANOVIRICIDES, INC. (NNVC).
Where is NANOVIRICIDES, INC. headquartered?
NANOVIRICIDES, INC. (NNVC) is headquartered in Shelton, CT, United States.
What therapeutic areas does NANOVIRICIDES, INC. focus on?
NANOVIRICIDES, INC. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.